A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S)

Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of cardiovascular events and mortality. Secukinumab selectively neutralizes IL-17A and has demonstrated high efficacy with a favorable safety profile in various psoriatic disease manifestations.

Source: Journal of Investigative Dermatology - February 19, 2020 Category: Dermatology Authors: Joel M. Gelfand, Daniel B. Shin, Kristina Callis Duffin, April W. Armstrong, Andrew Blauvelt, Stephen K. Tyring, Alan Menter, Scott Gottlieb, Benjamin N. Lockshin, Eric L. Simpson, Farid Kianifard, Rajendra Prasad Sarkar, Elisa Muscianisi, Jennifer Steadm Tags: Original Article Source Type: research